PMID- 31551787
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Erxian Decoction Attenuates TNF-alpha Induced Osteoblast Apoptosis by Modulating the 
      Akt/Nrf2/HO-1 Signaling Pathway.
PG  - 988
LID - 10.3389/fphar.2019.00988 [doi]
LID - 988
AB  - Erxian decoction (EXD), a traditional Chinese medicine formula, has been used for 
      treatment of osteoporosis for many years. The purpose of this study was to 
      investigate the pharmacological effect of EXD in preventing osteoblast apoptosis 
      and the underlying mechanism of prevention. Putative targets of EXD were 
      predicted by network pharmacology, and functional and pathway enrichment analyses 
      were also performed. Evaluations of bone mineral density, serum estradiol level, 
      trabecular area fraction, serum calcium levels, and tumor necrosis factor (TNF)-alpha 
      levels in ovariectomized rats, as well as cell proliferation assays, apoptosis 
      assays, and western blotting in MC3T3-E1 osteoblasts were performed for further 
      experimental validation. Ninety-three active ingredients in the EXD formula and 
      259 potential targets were identified. Functional and pathway enrichment analyses 
      indicated that EXD significantly influenced the PI3K-Akt signaling pathway. In 
      vivo experiments indicated that EXD treatment attenuated bone loss and decreased 
      TNF-alpha levels in rats with osteoporosis. In vitro experiments showed that EXD 
      treatment increased cell viability markedly and decreased levels of caspase-3 and 
      the rate of apoptosis. It also promoted phosphorylation of Akt, nuclear 
      translocation of transcription factor NF-erythroid 2-related factor (Nrf2), and 
      hemeoxygenase-1 (HO-1) expression in TNF-alpha-induced MC3T3-E1 cells. Our results 
      suggest that EXD exerted profound anti-osteoporosis effects, at least partially 
      by reducing production of TNF-alpha and attenuating osteoblast apoptosis via 
      Akt/Nrf2/HO-1 signaling pathway.
FAU - Wang, Nani
AU  - Wang N
AD  - Department of Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
AD  - School of Pharmacy, Zhejiang Chinese Medical University, China.
FAU - Xin, Hailiang
AU  - Xin H
AD  - School of Pharmacy, Second Military Medical University, China.
FAU - Xu, Pingcui
AU  - Xu P
AD  - Department of Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
AD  - School of Pharmacy, Zhejiang Chinese Medical University, China.
FAU - Yu, Zhongming
AU  - Yu Z
AD  - Department of Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
FAU - Shou, Dan
AU  - Shou D
AD  - Department of Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20190910
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6748068
OTO - NOTNLM
OT  - Akt
OT  - Erxian decoction
OT  - network pharmacology
OT  - osteoporosis
OT  - tumor necrosis factor
EDAT- 2019/09/26 06:00
MHDA- 2019/09/26 06:01
PMCR- 2019/09/10
CRDT- 2019/09/26 06:00
PHST- 2018/10/05 00:00 [received]
PHST- 2019/07/31 00:00 [accepted]
PHST- 2019/09/26 06:00 [entrez]
PHST- 2019/09/26 06:00 [pubmed]
PHST- 2019/09/26 06:01 [medline]
PHST- 2019/09/10 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00988 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Sep 10;10:988. doi: 10.3389/fphar.2019.00988. eCollection 
      2019.